By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



29 Newbury Street

Boston  Massachusetts  02116  U.S.A.
Phone: 617-236-0535 Fax: 617-249-0490


Start Up

Company News
Zafgen (ZFGN) To Present At Upcoming Investor Conferences 2/2/2016 8:04:49 AM
Zafgen (ZFGN) Falls as Hedge Fund Shorts Stock, Claims Obesity Drug Will Not Gain FDA Approval 1/25/2016 9:20:46 AM
Investors Rejoice as Zafgen (ZFGN)'s Obesity Drug Performs Well in Phase III Study, New Data May Lift Clinical Hold 1/20/2016 6:11:11 AM
Zafgen (ZFGN) Plunges Some More After FDA Orders Full Clinical Hold on Beloranib 12/3/2015 7:23:53 AM
Zafgen (ZFGN) Plagued By More Bad News as Second Patient Dies in Obesity Drug Trial 12/2/2015 6:18:53 AM
Zafgen (ZFGN) Announces Third Quarter 2015 Financial Results 11/11/2015 8:27:52 AM
Embattled Zafgen (ZFGN) Continues Obesity Clinical Trials Despite Patient Death and Pending Class Action Lawsuit 10/22/2015 6:35:48 AM
After Patient Death in Zafgen (ZFGN)'s Phase III Obesity Study, FDA Places Partial Hold on Trial 10/16/2015 6:10:33 AM
Zafgen (ZFGN) Issues Statement 10/15/2015 7:25:41 AM
Breaking News: Zafgen (ZFGN) Breaks Silence About Death in Phase III Obesity Clinical Trial 10/14/2015 7:09:57 AM